Delta4 at BIO-Europe 2023: Fostering Partnerships and Driving Innovation We are excited to share Delta4’s presence at the recently concluded […]
Author: Kurt Herpel
What to Expect From The Pharmaceutical Industry In 2024
As we step into 2024, the pharmaceutical industry stands at the cusp of remarkable advancements and significant transformations. This year […]
Digital Health Envision Summit
We are delighted to announce that Dr. Klaus Kratochwill, CSO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are […]
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to […]
Delta4 at RExPO: Pushing the Boundaries of Drug Repurposing
We are thrilled to announce that Delta4 will be in attendance at this year’s RExPO23, a landmark event in the […]
Reactome Spotlights Delta4’s Computational Drug Repositioning of Clopidogrel for FSGS
We are honored to announce that our publication on the computational drug repositioning of clopidogrel has been highlighted in the […]
Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)
The scientific goal of PerMediK is to foster development toward personalized medicine in chronic kidney disease (CKD), based on multidimensional […]
Protected: AI Drug Discovery Services Companies Forging the Future of Medicine
There is no excerpt because this is a protected post.
Delta4’s Innovation Shines: OntoloViz Article Published in Bioinformatics Advances Journal
We are thrilled to announce that our journal article, titled “OntoloViz: a GUI for interactive visualization of ranked disease or […]
Drug Indication Expansion: Unlocking Untapped Potential
In the vast ecosystem of the pharmaceutical industry, drug indication expansion plays a pivotal role in maximizing the potential of […]